




RealRate

PHARMACEUTICAL 2022

Karyopharm Therapeutics Inc.
Rank 288 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 185% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 105% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	275,606
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	73,718
Liabilities, Non-Current	8,969
Other Assets	28,057
Other Compr. Net Income	-327
Other Expenses	3,670
Other Liabilities	302,291
Other Net Income	-25,549
Property and Equipment	1,642
Research and Development	160,842
Revenues	209,819
Selling, General and Administrative Expense	143,846

Output Variable	Value in 1000 USD
Assets	305,305
Liabilities	384,978
Expenses	308,358
Stockholders Equity	-79,673
Net Income	-124,088
Comprehensive Net Income	-124,252
Economic Capital Ratio	-172%